These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Reversal of some viral IL-6 electrostatic properties compared to IL-6 contributes to a loss of alpha receptor component recruitment. Perret D; Rousseau F; Tran V; Gascan H Proteins; 2005 Jul; 60(1):14-26. PubMed ID: 15861391 [TBL] [Abstract][Full Text] [Related]
7. Interleukin-6 trans-signalling in chronic inflammation and cancer. Scheller J; Ohnesorge N; Rose-John S Scand J Immunol; 2006 May; 63(5):321-9. PubMed ID: 16640655 [TBL] [Abstract][Full Text] [Related]
8. The soluble IL-6 receptors: serum levels and biological function. Montero-Julian FA Cell Mol Biol (Noisy-le-grand); 2001 Jun; 47(4):583-97. PubMed ID: 11502067 [TBL] [Abstract][Full Text] [Related]
9. Identification of two novel regions of human IL-6 responsible for receptor binding and signal transduction. Ehlers M; Grötzinger J; deHon FD; Müllberg J; Brakenhoff JP; Liu J; Wollmer A; Rose-John S J Immunol; 1994 Aug; 153(4):1744-53. PubMed ID: 7519211 [TBL] [Abstract][Full Text] [Related]
10. The family of the IL-6-type cytokines: specificity and promiscuity of the receptor complexes. Grötzinger J; Kurapkat G; Wollmer A; Kalai M; Rose-John S Proteins; 1997 Jan; 27(1):96-109. PubMed ID: 9037715 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of interleukin-6-transsignaling via gp130-Fc in hemorrhagic shock and sepsis. Mees ST; Toellner S; Marx K; Faendrich F; Kallen KJ; Schroeder J; Haier J; Kahlke V J Surg Res; 2009 Dec; 157(2):235-42. PubMed ID: 19589542 [TBL] [Abstract][Full Text] [Related]
12. Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptor. Skiniotis G; Boulanger MJ; Garcia KC; Walz T Nat Struct Mol Biol; 2005 Jun; 12(6):545-51. PubMed ID: 15895091 [TBL] [Abstract][Full Text] [Related]
14. IL-6 transsignaling: the in vivo consequences. Jones SA; Richards PJ; Scheller J; Rose-John S J Interferon Cytokine Res; 2005 May; 25(5):241-53. PubMed ID: 15871661 [TBL] [Abstract][Full Text] [Related]
15. A novel and rapid prediction assay for the effectiveness of IL-6 receptor specific antisense oligonucleotides by proliferation inhibition of an interleukin-6 dependent cell line. Lia Varga V; Falus A; Pallinger E; Novák I; Fülöp KA; Toth S; Rose-John S Cell Biol Int; 2001; 25(3):253-6. PubMed ID: 11352498 [TBL] [Abstract][Full Text] [Related]
16. IL-6 transsignalling modulates the early effector phase of EAE and targets the blood-brain barrier. Linker RA; Lühder F; Kallen KJ; Lee DH; Engelhardt B; Rose-John S; Gold R J Neuroimmunol; 2008 Dec; 205(1-2):64-72. PubMed ID: 18950871 [TBL] [Abstract][Full Text] [Related]
17. The opioid ligand binding of human mu-opioid receptor is modulated by novel splice variants of the receptor. Choi HS; Kim CS; Hwang CK; Song KY; Wang W; Qiu Y; Law PY; Wei LN; Loh HH Biochem Biophys Res Commun; 2006 May; 343(4):1132-40. PubMed ID: 16580639 [TBL] [Abstract][Full Text] [Related]
18. Alternative splicing of mRNA of mouse interleukin-4 and interleukin-6. Yatsenko OP; Filipenko ML; Khrapov EA; Voronina EN; Kozlov VA; Sennikov SV Cytokine; 2004 Nov 21-Dec 7; 28(4-5):190-6. PubMed ID: 15588696 [TBL] [Abstract][Full Text] [Related]
19. Determinants governing the potency of STAT3 activation via the individual STAT3-recruiting motifs of gp130. Lehmann U; Sommer U; Smyczek T; Hörtner M; Frisch W; Volkmer-Engert R; Heinrich PC; Schaper F; Haan S Cell Signal; 2006 Jan; 18(1):40-9. PubMed ID: 15927449 [TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 trans-signaling in inflammatory bowel disease. Mitsuyama K; Sata M; Rose-John S Cytokine Growth Factor Rev; 2006 Dec; 17(6):451-61. PubMed ID: 17045835 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]